alexa Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
Ophthalmology

Ophthalmology

Journal of Clinical & Experimental Ophthalmology

Author(s): You IC, Im SK, Lee SH, Yoon KC

Abstract Share this page

Abstract PURPOSE: To investigate the efficacy of combined photodynamic therapy with verteporfin and subconjunctival injection of bevacizumab for the treatment of patients with corneal neovascularization. METHODS: Twelve eyes of 12 patients with stable corneal neovascularization who were refractory to conventional treatment were treated with photodynamic therapy with verteporfin (6 mg/m) and subconjunctival injection of bevacizumab (2.5 mg/0.1 mL). Anterior segment photography was performed before and after treatment. Best-corrected visual acuity, cumulative length of corneal blood vessels, and area of corneal neovascularization were measured. RESULTS: From 1 week to 1 month after treatment, all eyes showed a notable decrease in corneal neovascularization and evidence of vascular thrombosis. At the 6-month and 1-year follow-ups, complete vascular occlusion was achieved in 8 eyes (66.7\%) and partial occlusion was achieved in 3 eyes (25.0\%). One eye (8.3\%) showed revascularization after temporary occlusion. No ocular complications or systemic events developed. CONCLUSIONS: Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab seems to be effective for the treatment of corneal neovascularization. This article was published in Cornea and referenced in Journal of Clinical & Experimental Ophthalmology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords